Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1947 1
1958 1
1961 2
1962 1
1964 2
1965 4
1967 2
1968 2
1971 1
1972 7
1973 3
1974 2
1975 1
1976 3
1977 1
1980 1
1982 1
1983 1
1988 1
1995 1
1997 1
1998 2
1999 3
2000 1
2001 5
2002 1
2003 2
2004 2
2005 4
2006 3
2007 7
2008 3
2009 3
2010 3
2011 3
2012 8
2013 10
2014 6
2015 12
2016 6
2017 7
2018 12
2019 12
2020 17
2021 15
2022 18
2023 12
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

213 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV, Ascierto PA, Mandala M, De Galitiis F, Haydon A, Dummer R, Grob JJ, Robert C, Carlino MS, Mohr P, Poklepovic A, Sondak VK, Scolyer RA, Kirkwood JM, Chen K, Diede SJ, Ahsan S, Ibrahim N, Eggermont AMM; KEYNOTE-716 Investigators. Luke JJ, et al. Among authors: mackiewicz j. Lancet. 2022 Apr 30;399(10336):1718-1729. doi: 10.1016/S0140-6736(22)00562-1. Epub 2022 Apr 1. Lancet. 2022. PMID: 35367007 Clinical Trial.
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.
Long GV, Luke JJ, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob JJ, de Galitiis F, Schadendorf D, Carlino MS, Mohr P, Dummer R, Gershenwald JE, Yoon CH, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Ascierto PA; KEYNOTE-716 Investigators. Long GV, et al. Among authors: mackiewicz j. Lancet Oncol. 2022 Nov;23(11):1378-1388. doi: 10.1016/S1470-2045(22)00559-9. Epub 2022 Oct 18. Lancet Oncol. 2022. PMID: 36265502 Clinical Trial.
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
Kirkwood JM, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA, Menzies AM, Durani P, Lobo M, Campigotto F, Gastman B, Long GV. Kirkwood JM, et al. Among authors: mackiewicz j. Nat Med. 2023 Nov;29(11):2835-2843. doi: 10.1038/s41591-023-02583-2. Epub 2023 Oct 16. Nat Med. 2023. PMID: 37845511 Free PMC article. Clinical Trial.
Targeting CaN/NFAT in Alzheimer's brain degeneration.
Mackiewicz J, Lisek M, Boczek T. Mackiewicz J, et al. Front Immunol. 2023 Nov 23;14:1281882. doi: 10.3389/fimmu.2023.1281882. eCollection 2023. Front Immunol. 2023. PMID: 38077352 Free PMC article. Review.
lncRNA in HNSCC: challenges and potential.
Guglas K, Bogaczyńska M, Kolenda T, Ryś M, Teresiak A, Bliźniak R, Łasińska I, Mackiewicz J, Lamperska K. Guglas K, et al. Among authors: mackiewicz j. Contemp Oncol (Pozn). 2017;21(4):259-266. doi: 10.5114/wo.2017.72382. Epub 2017 Dec 30. Contemp Oncol (Pozn). 2017. PMID: 29416430 Free PMC article. Review.
Changes in Tear Proteomic Profile in Ocular Diseases.
Winiarczyk M, Biela K, Michalak K, Winiarczyk D, Mackiewicz J. Winiarczyk M, et al. Among authors: mackiewicz j. Int J Environ Res Public Health. 2022 Oct 16;19(20):13341. doi: 10.3390/ijerph192013341. Int J Environ Res Public Health. 2022. PMID: 36293921 Free PMC article. Review.
Integrins as A New Target for Cancer Treatment.
Łasiñska I, Mackiewicz J. Łasiñska I, et al. Among authors: mackiewicz j. Anticancer Agents Med Chem. 2019;19(5):580-586. doi: 10.2174/1871520618666181119103413. Anticancer Agents Med Chem. 2019. PMID: 30451118 Review.
Caryophyllidea (Cestoidea): a review.
Mackiewicz JS. Mackiewicz JS. Exp Parasitol. 1972 Jun;31(3):417-512. doi: 10.1016/0014-4894(72)90103-8. Exp Parasitol. 1972. PMID: 4558418 Review. No abstract available.
213 results